BTK and non-Hodgkin lymphoma: In patients with indolent NHL, negative antibody response was present on different treatment regimens: 7/8 patients were on BTK inhibitor (ibrutinib or acalabrutinib), and 5/8 patients were on rituximab-based chemotherapy.